METHODS FOR TREATING LOWER RISK MYELODYSPLASTIC SYNDROME

The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith. La présente invention concerne l'utilisation de pelabresib, et de sels et d'hy...

Full description

Saved in:
Bibliographic Details
Main Authors LUPTAKOVA, Katarina, HAERTLE, Stefan
Format Patent
LanguageEnglish
French
Published 27.06.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to the use of pelabresib, and pharmaceutically acceptable salts and hydrates thereof, for treating lower risk myelodysplastic syndrome (LR-MDS) and conditions associated therewith. La présente invention concerne l'utilisation de pelabresib, et de sels et d'hydrates pharmaceutiquement acceptables de celui-ci, pour le traitement du syndrome myélodysplasique à risque inférieur (LR-MDS) et d'états associés à celui-ci.
Bibliography:Application Number: WO2023US84959